Tomas Phillipson has been appointed as Strategic Advisor for Soligenix, a late-stage biopharmaceutical company based in Princeton.
Soligenix is a company that works on developing and commercializing products to treat rare diseases where there is an unmet medical need.
The company’s current main focus is its lead product candidate HyBryte, currently in a confirmatory Phase 3 clinical trial.
Philipson currently serves as managing partner of the venture capital firm MEDA Ventures and has co-founded several companies, including Precision Health Economics LLC.
His government service includes a full-time position as vice chairman and acting chairman of President Trump’s White House Council of Economic Advisers from 2017 to 2020. He previously served as a senior economic adviser to the head of the U.S. Food and Drug Administration and a senior economic advisor to the head of the Centers for Medicare and Medicaid Services.
Soligenix President Christopher Schaber thought highly of his background.
“His extensive experience and relationships at the highest levels of government, including with FDA and CMS, as well as his business savvy brings a vital perspective to today’s policy environment, from healthcare innovation to long-term economic competitiveness,” he said.
Philipson has received numerous honors, being a two-time winner of the Arrow Award of The International Health Economics Association, the highest honor in health economics. Other awards include the Garfield Award for Economic Research, the Prêmio Haralambos Simeonidis from the Brazilian Economic Association, and the Milken Institute’s Distinguished Economic Research Award.
